{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:46:46Z","timestamp":1792691206105,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN-PNRR P2022E4MLS"],"award-info":[{"award-number":["PRIN-PNRR P2022E4MLS"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-025-03431-2","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T06:04:05Z","timestamp":1750745045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting individual treatment response in alcohol use disorders: a reverse translational proof-of-concept study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3788-196X","authenticated-orcid":false,"given":"Sara","family":"De Carlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hela","family":"Mrizak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Della Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Lunerti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manthoula O.","family":"Kyratzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mammone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lacorte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adana","family":"Keshishian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esi","family":"Domi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah Solberg","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Soverchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Ubaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3126-9240","authenticated-orcid":false,"given":"Roberto","family":"Ciccocioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-8679","authenticated-orcid":false,"given":"Nazzareno","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"3431_CR1","unstructured":"WHO. Global status report on alcohol and health. World Health Organization editors. Switzerland, 2018."},{"key":"3431_CR2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/bmj.1.6017.1058","volume":"1","author":"G Edwards","year":"1976","unstructured":"Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. Br Med J. 1976;1:1058\u201361.","journal-title":"Br Med J"},{"key":"3431_CR3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.15288\/jsa.1976.37.1360","volume":"37","author":"G Edwards","year":"1976","unstructured":"Edwards G, Gross MM, Keller M, Moser J. Alcohol-related problems in the disability perspective. A summary of the consensus of the WHO group of investigators on criteria for identifying and classifying disabilities related to alcohol consumption. J Stud Alcohol. 1976;37:1360\u201382.","journal-title":"J Stud Alcohol"},{"key":"3431_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1152\/physrev.00013.2008","volume":"89","author":"R Spanagel","year":"2009","unstructured":"Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. 2009;89:649\u2013705.","journal-title":"Physiol Rev"},{"key":"3431_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.tips.2007.12.005","volume":"29","author":"R Spanagel","year":"2008","unstructured":"Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci. 2008;29:109\u201315.","journal-title":"Trends Pharmacol Sci"},{"key":"3431_CR6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrn3110","volume":"12","author":"M Heilig","year":"2011","unstructured":"Heilig M, Goldman D, Berrettini W, O\u2019Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nature reviews Neuroscience. 2011;12:670\u201384.","journal-title":"Nature reviews Neuroscience"},{"key":"3431_CR7","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311:1889\u20131900.","journal-title":"JAMA"},{"key":"3431_CR8","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1038\/npp.2016.61","volume":"41","author":"ML Schwandt","year":"2016","unstructured":"Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R, et al. The CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology. 2016;41:2818\u201329.","journal-title":"Neuropsychopharmacology"},{"key":"3431_CR9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/npp.2014.306","volume":"40","author":"LE Kwako","year":"2015","unstructured":"Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R, et al. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology. 2015;40:1053\u201363.","journal-title":"Neuropsychopharmacology"},{"key":"3431_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","volume":"36","author":"RZ Litten","year":"2012","unstructured":"Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36:406\u201316.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR11","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/j.1530-0277.2011.01716.x","volume":"36","author":"JB Fertig","year":"2012","unstructured":"Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36:1421\u201330.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/science.329.5991.502","volume":"329","author":"G Miller","year":"2010","unstructured":"Miller G. Is pharma running out of brainy ideas? Science. 2010;329:502\u20134.","journal-title":"Science"},{"key":"3431_CR13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/clpt.2009.295","volume":"87","author":"JA DiMasi","year":"2010","unstructured":"DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"3431_CR14","doi-asserted-by":"publisher","first-page":"155cm111","DOI":"10.1126\/scitranslmed.3003142","volume":"4","author":"SE Hyman","year":"2012","unstructured":"Hyman SE. Revolution stalled. Sci Transl Med. 2012;4:155cm111.","journal-title":"Sci Transl Med"},{"key":"3431_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/7854_2015_5006","volume":"28","author":"M Heilig","year":"2016","unstructured":"Heilig M, Sommer WH, Spanagel R. The need for treatment responsive translational biomarkers in alcoholism research. Curr Top Behav Neurosci. 2016;28:151\u201371.","journal-title":"Curr Top Behav Neurosci"},{"key":"3431_CR16","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1007\/s00406-010-0153-7","volume":"260","author":"K Mann","year":"2010","unstructured":"Mann K, Hermann D. Individualised treatment in alcohol-dependent patients. Eur Arch Psychiatry Clin Neurosci. 2010;260:S116\u2013120.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3431_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72:757\u201366.","journal-title":"JAMA Psychiatry"},{"key":"3431_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/bs.pbr.2015.07.023","volume":"224","author":"M Heilig","year":"2016","unstructured":"Heilig M, Leggio L. What the alcohol doctor ordered from the neuroscientist: theragnostic biomarkers for personalized treatments. Prog Brain Res. 2016;224:401\u201318.","journal-title":"Prog Brain Res"},{"key":"3431_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.neubiorev.2019.05.014","volume":"103","author":"N Cannella","year":"2019","unstructured":"Cannella N, Ubaldi M, Masi A, Bramucci M, Roberto M, Bifone A, et al. Building better strategies to develop new medications in alcohol use disorder: learning from past success and failure to shape a brighter future. Neurosci Biobehav Rev. 2019;103:384\u201398.","journal-title":"Neurosci Biobehav Rev"},{"key":"3431_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/npp.2017.105","volume":"43","author":"C Giuliano","year":"2018","unstructured":"Giuliano C, Pena-Oliver Y, Goodlett CR, Cardinal RN, Robbins TW, Bullmore ET, et al. Evidence for a long-lasting compulsive alcohol seeking phenotype in rats. Neuropsychopharmacology. 2018;43:728\u201338.","journal-title":"Neuropsychopharmacology"},{"key":"3431_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fnbeh.2019.00003","volume":"13","author":"A Domi","year":"2019","unstructured":"Domi A, Stopponi S, Domi E, Ciccocioppo R, Cannella N. Sub-dimensions of alcohol use disorder in alcohol preferring and non-preferring rats, a comparative study. Front Behav Neurosci. 2019;13:3.","journal-title":"Front Behav Neurosci"},{"key":"3431_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09801-1","volume":"7","author":"KS Jadhav","year":"2017","unstructured":"Jadhav KS, Magistretti PJ, Halfon O, Augsburger M, Boutrel B. A preclinical model for identifying rats at risk of alcohol use disorder. Sci Rep. 2017;7:9454.","journal-title":"Sci Rep"},{"key":"3431_CR23","doi-asserted-by":"publisher","first-page":"eabg9045","DOI":"10.1126\/sciadv.abg9045","volume":"7","author":"E Domi","year":"2021","unstructured":"Domi E, Xu L, Toivainen S, Nordeman A, Gobbo F, Venniro M, et al. A neural substrate of compulsive alcohol use. Sci Adv. 2021;7:eabg9045.","journal-title":"Sci Adv"},{"key":"3431_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/acer.12619","volume":"39","author":"S Krishnan-Sarin","year":"2015","unstructured":"Krishnan-Sarin S, O\u2019Malley SS, Franco N, Cavallo DA, Morean M, Shi J, et al. N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers. Alcohol Clin Exp Res. 2015;39:300\u20137.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1530-0277.2007.00360.x","volume":"31","author":"SM Evans","year":"2007","unstructured":"Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of Memantine for alcohol dependence. Alcohol Clin Exp Res. 2007;31:775\u201382.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/10550887.2020.1721404","volume":"38","author":"B Lewis","year":"2020","unstructured":"Lewis B, Merlo L, Greene W, Welch E, Nixon SJ. Randomized trial to assess safety\/feasibility of Memantine administration during residential treatment for alcohol use disorder: a pilot study. J Addict Dis. 2020;38:91\u201399.","journal-title":"J Addict Dis"},{"key":"3431_CR27","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/adb.12425","volume":"22","author":"CS Hendershot","year":"2017","unstructured":"Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J. Effects of Naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. Addict Biol. 2017;22:1515\u201327.","journal-title":"Addict Biol"},{"key":"3431_CR28","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA. 2023;330:1653\u201365.","journal-title":"JAMA"},{"key":"3431_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/ng.124","volume":"40","author":"K Saar","year":"2008","unstructured":"Consortium S, Saar K, Beck A, Bihoreau MT, Birney E, Brocklebank D, et al. SNP and haplotype mapping for genetic analysis in the rat. Nat Genet. 2008;40:560\u20136.","journal-title":"Nat Genet"},{"key":"3431_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1101\/gr.081497.108","volume":"19","author":"M Johannesson","year":"2009","unstructured":"Johannesson M, Lopez-Aumatell R, Stridh P, Diez M, Tuncel J, Blazquez G, et al. A resource for the simultaneous high-resolution mapping of multiple quantitative trait loci in rats: the NIH heterogeneous stock. Genome Res. 2009;19:150\u20138.","journal-title":"Genome Res"},{"key":"3431_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1530-0277.1984.tb05706.x","volume":"8","author":"C Hansen","year":"1984","unstructured":"Hansen C, Spuhler K. Development of the National Institutes of Health genetically heterogeneous rat stock. Alcohol Clin Exp Res. 1984;8:477\u20139.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.bbi.2024.03.003","volume":"118","author":"N Cannella","year":"2024","unstructured":"Cannella N, Tambalo S, Lunerti V, Scuppa G, de Vivo L, Abdulmalek S, et al. Long-access heroin self-administration induces region specific reduction of grey matter volume and microglia reactivity in the rat. Brain Behav Immun. 2024;118:210\u201320.","journal-title":"Brain Behav Immun"},{"key":"3431_CR33","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1007\/s00213-022-06235-0","volume":"239","author":"BN Kuhn","year":"2022","unstructured":"Kuhn BN, Cannella N, Crow AD, Roberts AT, Lunerti V, Allen C, et al. Novelty-induced locomotor behavior predicts heroin addiction vulnerability in male, but not female, rats. Psychopharmacology. 2022;239:3605\u201320.","journal-title":"Psychopharmacology"},{"key":"3431_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.745468","volume":"12","author":"C Allen","year":"2021","unstructured":"Allen C, Kuhn BN, Cannella N, Crow AD, Roberts AT, Lunerti V, et al. Network-based discovery of opioid use vulnerability in rats using the bayesian stochastic block model. Front Psychiatry. 2021;12:745468.","journal-title":"Front Psychiatry"},{"key":"3431_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.alcohol.2020.11.007","volume":"91","author":"A Deal","year":"2021","unstructured":"Deal A, Cooper N, Kirse HA, Uneri A, Raab-Graham K, Weiner JL, et al. Early life stress induces hyperactivity but not increased anxiety-like behavior or ethanol drinking in outbred heterogeneous stock rats. Alcohol. 2021;91:41\u201351.","journal-title":"Alcohol"},{"key":"3431_CR36","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1073\/pnas.1915143117","volume":"117","author":"M Kallupi","year":"2020","unstructured":"Kallupi M, Carrette LLG, Kononoff J, Solberg Woods LC, Palmer AA, Schweitzer P, et al. Nociceptin attenuates the escalation of oxycodone self-administration by normalizing CeA-GABA transmission in highly addicted rats. Proc Natl Acad Sci USA. 2020;117:2140\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3431_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcpt.12479","volume":"118","author":"SH Lee","year":"2016","unstructured":"Lee SH, Kim SH, Noh YH, Choi BM, Noh GJ, Park WD, et al. Pharmacokinetics of Memantine after a single and multiple dose of oral and patch administration in rats. Basic Clin Pharmacol Toxicol. 2016;118:122\u20137.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3431_CR38","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1111\/bph.15210","volume":"177","author":"E Domi","year":"2020","unstructured":"Domi E, Xu L, Patz M, Nordeman A, Augier G, Holm L, et al. Nicotine increases alcohol self-administration in male rats via a mu-opioid mechanism within the mesolimbic pathway. Br J Pharmacol. 2020;177:4516\u201331.","journal-title":"Br J Pharmacol"},{"key":"3431_CR39","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/adb.12177","volume":"20","author":"S Alaux-Cantin","year":"2015","unstructured":"Alaux-Cantin S, Buttolo R, Houchi H, Jeanblanc J, Naassila M. Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. Addict Biol. 2015;20:890\u2013901.","journal-title":"Addict Biol"},{"key":"3431_CR40","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/adb.12039","volume":"19","author":"J Jeanblanc","year":"2014","unstructured":"Jeanblanc J, Coune F, Botia B, Naassila M. Brain-derived neurotrophic factor mediates the suppression of alcohol self-administration by Memantine. Addict Biol. 2014;19:758\u201369.","journal-title":"Addict Biol"},{"key":"3431_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bbr.2013.02.030","volume":"247","author":"V Sabino","year":"2013","unstructured":"Sabino V, Narayan AR, Zeric T, Steardo L, Cottone P. mTOR activation is required for the anti-alcohol effect of ketamine, but not Memantine, in alcohol-preferring rats. Behav Brain Res. 2013;247:9\u201316.","journal-title":"Behav Brain Res"},{"key":"3431_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0014-2999(98)00442-7","volume":"354","author":"J Piasecki","year":"1998","unstructured":"Piasecki J, Koros E, Dyr W, Kostowski W, Danysz W, Bienkowski P. Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, Memantine. Eur J Pharmacol. 1998;354:135\u201343.","journal-title":"Eur J Pharmacol"},{"key":"3431_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.alcohol.2008.11.003","volume":"43","author":"KL Williams","year":"2009","unstructured":"Williams KL, Broadbridge CL. Potency of Naltrexone to reduce ethanol self-administration in rats is greater for subcutaneous versus intraperitoneal injection. Alcohol. 2009;43:119\u201326.","journal-title":"Alcohol"},{"key":"3431_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0741-8329(97)00131-6","volume":"15","author":"MF Stromberg","year":"1998","unstructured":"Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O\u2019Brien CP. A comparison of the effects of the opioid antagonists Naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol. 1998;15:281\u20139.","journal-title":"Alcohol"},{"key":"3431_CR45","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/14740338.2018.1524870","volume":"17","author":"S Matsunaga","year":"2018","unstructured":"Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T, et al. The efficacy and safety of Memantine for the treatment of Alzheimer\u2019s disease. Expert Opin Drug Saf. 2018;17:1053\u201361.","journal-title":"Expert Opin Drug Saf"},{"key":"3431_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1176\/ajp.2007.164.3.519","volume":"164","author":"EM Krupitsky","year":"2007","unstructured":"Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T, et al. Effect of Memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry. 2007;164:519\u201323.","journal-title":"Am J Psychiatry"},{"key":"3431_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00213-003-1617-5","volume":"172","author":"A Bisaga","year":"2004","unstructured":"Bisaga A, Evans SM. Acute effects of Memantine in combination with alcohol in moderate drinkers. Psychopharmacology. 2004;172:16\u201324.","journal-title":"Psychopharmacology"},{"key":"3431_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41386-019-0536-z","volume":"45","author":"S Krishnan-Sarin","year":"2020","unstructured":"Krishnan-Sarin S, O\u2019Malley SS, Franco N, Cavallo DA, Tetrault JM, Shi J, et al. Influence of combined treatment with Naltrexone and Memantine on alcohol drinking behaviors: a phase II randomized crossover trial. Neuropsychopharmacology. 2020;45:319\u201326.","journal-title":"Neuropsychopharmacology"},{"key":"3431_CR49","first-page":"101","volume":"1","author":"AC Chen","year":"2013","unstructured":"Chen AC, Morgenstern J, Davis CM, Kuerbis AN, Covault J, Kranzler HR. Variation in Mu-opioid receptor gene (OPRM1) as a moderator of Naltrexone treatment to reduce heavy drinking in a high functioning cohort. J Alcohol Drug Depend. 2013;1:101.","journal-title":"J Alcohol Drug Depend"},{"key":"3431_CR50","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/npp.2017.74","volume":"42","author":"JP Schacht","year":"2017","unstructured":"Schacht JP, Randall PK, Latham PK, Voronin KE, Book SW, Myrick H, et al. Predictors of Naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status. Neuropsychopharmacology. 2017;42:2640\u201353.","journal-title":"Neuropsychopharmacology"},{"key":"3431_CR51","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/acer.14431","volume":"44","author":"RF Anton","year":"2020","unstructured":"Anton RF, Voronin KE, Book SW, Latham PK, Randall PK, Glen WB, et al. Opioid and dopamine genes interact to predict Naltrexone response in a randomized alcohol use disorder clinical trial. Alcohol Clin Exp Res. 2020;44:2084\u201396.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1530-0277.2008.00804.x","volume":"33","author":"MP Bogenschutz","year":"2009","unstructured":"Bogenschutz MP, Scott Tonigan J, Pettinati HM. Effects of alcoholism typology on response to Naltrexone in the COMBINE study. Alcohol Clin Exp Res. 2009;33:10\u201318.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/alcalc\/agn122","volume":"44","author":"JC Garbutt","year":"2009","unstructured":"Garbutt JC, Osborne M, Gallop R, Barkenbus J, Grace K, Cody M, et al. Sweet liking phenotype, alcohol craving and response to Naltrexone treatment in alcohol dependence. Alcohol Alcohol. 2009;44:293\u2013300.","journal-title":"Alcohol Alcohol"},{"key":"3431_CR54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/npp.2017.282","volume":"43","author":"K Mann","year":"2018","unstructured":"Mann K, Roos CR, Hoffmann S, Nakovics H, Lemenager T, Heinz A, et al. Precision Medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes. Neuropsychopharmacology. 2018;43:891\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"3431_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109257","volume":"232","author":"VR Votaw","year":"2022","unstructured":"Votaw VR, Mann K, Kranzler HR, Roos CR, Nakovics H, Witkiewitz K. Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response. Drug Alcohol Depend. 2022;232:109257.","journal-title":"Drug Alcohol Depend"},{"key":"3431_CR56","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1111\/acer.12546","volume":"38","author":"K Mann","year":"2014","unstructured":"Mann K, Vollstadt-Klein S, Reinhard I, Lemenager T, Fauth-Buhler M, Hermann D, et al. Predicting Naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. Alcohol Clin Exp Res. 2014;38:2754\u201362.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.neuroimage.2013.03.055","volume":"78","author":"SE Lukas","year":"2013","unstructured":"Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, et al. Extended-release Naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Neuroimage. 2013;78:176\u201385.","journal-title":"Neuroimage"},{"key":"3431_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1369-1600.2012.00464.x","volume":"18","author":"JP Schacht","year":"2013","unstructured":"Schacht JP, Anton RF, Myrick H. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol. 2013;18:121\u201333.","journal-title":"Addict Biol"},{"key":"3431_CR59","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1460-9568.2010.07590.x","volume":"33","author":"S Kuhn","year":"2011","unstructured":"Kuhn S, Gallinat J. Common biology of craving across legal and illegal drugs - a quantitative meta-analysis of cue-reactivity brain response. Eur J Neurosci. 2011;33:1318\u201326.","journal-title":"Eur J Neurosci"},{"key":"3431_CR60","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.pbb.2004.08.018","volume":"79","author":"ZA Rodd","year":"2004","unstructured":"Rodd ZA, Bell RL, Sable HJ, Murphy JM, McBride WJ. Recent advances in animal models of alcohol craving and relapse. Pharmacol Biochem Behav. 2004;79:439\u201350.","journal-title":"Pharmacol Biochem Behav"},{"key":"3431_CR61","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1046\/j.1360-0443.95.8s2.17.x","volume":"95","author":"GF Koob","year":"2000","unstructured":"Koob GF. Animal models of craving for ethanol. Addiction. 2000;95:S73\u201381.","journal-title":"Addiction"},{"key":"3431_CR62","first-page":"39","volume":"56","author":"JR Volpicelli","year":"1995","unstructured":"Volpicelli JR, Clay KL, Watson NT, O\u2019Brien CP. Naltrexone in the treatment of alcoholism: predicting response to Naltrexone. J Clin Psychiatry. 1995;56:39\u201344.","journal-title":"J Clin Psychiatry"},{"key":"3431_CR63","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1037\/0022-006X.64.5.1044","volume":"64","author":"AJ Jaffe","year":"1996","unstructured":"Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O\u2019Malley SS. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol. 1996;64:1044\u201353.","journal-title":"J Consult Clin Psychol"},{"key":"3431_CR64","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/105504901750532148","volume":"10","author":"JR Monterosso","year":"2001","unstructured":"Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O\u2019Brien CP, et al. Predicting treatment response to Naltrexone: the influence of craving and family history. Am J Addict. 2001;10:258\u201368.","journal-title":"Am J Addict"},{"key":"3431_CR65","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1530-0277.2008.00633.x","volume":"32","author":"AM Baros","year":"2008","unstructured":"Baros AM, Latham PK, Anton RF. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008;32:771\u20136.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR66","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/j.1530-0277.2010.01267.x","volume":"34","author":"SF Greenfield","year":"2010","unstructured":"Greenfield SF, Pettinati HM, O\u2019Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34:1803\u201312.","journal-title":"Alcohol Clin Exp Res"},{"key":"3431_CR67","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/JCP.0b013e3181ac5213","volume":"29","author":"HR Kranzler","year":"2009","unstructured":"Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, Arias A, et al. Targeted Naltrexone for problem drinkers. J Clin Psychopharmacol. 2009;29:350\u20137.","journal-title":"J Clin Psychopharmacol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03431-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03431-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03431-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T18:03:15Z","timestamp":1750788195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-025-03431-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3431"],"URL":"https:\/\/doi.org\/10.1038\/s41398-025-03431-2","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}